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Abstract
The mutagenic activity of four newly synthesized chemoterapic compounds, two from s-
triazole (antiparasite actions) and two from hydrazides (tuberculostatic effects), was analyzed by
the micronucleus assay in bone marrow of  mice and by the Salmonella/microsome assay.  In the
micronucleus assay, the animals were dosed orally by gavage with maximum tolerated dose
(MTD), single dose, and killed 24 and 48 hours after treatment. The Salmonella/microsome assay
was carried out with a preincubation method and Salmonella typhimurium strains TA98 and
TA100.  The results from the present study showed that both s-triazoles and both hydrazides did
not induce genotoxicity. Consequently, these results led to continue the efforts to evaluate the
pharmacological potentials of these products.
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Resumo
Neste trabalho foram avaliadas as atividades mutagênicas de quatro quimioterápicos no-
vos, dois sintetizados a partir do triazol (ação antiparasitária) e dois das hidrazidas (efeito sobre
a tuberculose). A avaliação mutagênica foi realisada utilizando-se o teste de micronúcleos em
camundongos e também o ensaio Salmonella / Teste de Ames. Para o teste de micronúcleos
utilizou-se dosagem oral da dose máxima tolerada, dosagem única (teste agudo), e sacrifício 24
e 48h após tratamento. Para o Teste de Ames utilizou-se duas linhagens de Salmonella
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typhimurium, TA98 e TA100. Os resultados do presente estudo para ambos compostos testados,
s-triazóis e hidrazidas, não mostram diferenças significativas em relação ao controle negativo,
sendo assim estas drogas consideradas não-mutagênicas pelos presentes testes.
Consequentemente, estes resultados permitem que sejam continuados os estudos dos potenci-
ais farmacológicos destes produtos.
Palavras-Chave: Teste de Ames, genotoxicidade, hidrazidas, micronúcleo, mutagenicidade, triazóis
Introduction
The use of genotoxic evaluation by the
modern Pharmaceutic Industry increased
very fast in the last decade.  This was due to
the necessity of toxicological evaluation of
drugs and the search for less toxic
compounds. The main interest of
pharmaceutic activities is focussed on
chemotherapic drugs.  The triazoles, with
their known antiparasite actions, and
hydrazides, with tuberculostatic effects, are
some of these drugs (YALE et al., 1953;
PIGNATELO et al., 1991; BAJI et al., 1995;
MIYAUCHI et al., 1995).  Many  of these
compounds and their derivatives
demonstrate structure-activity relationships
in mutagenicity and carcinogenicity
(CRAIG & ATITZEL, 1986; VELÁZQUEZ
et al., 1990; BURLINSN et al., 1991;
KNASMÜLLER & SZAKMARY, 1992;
ALBANO et al., 1993; BARALE et al., 1993;
ZANI et al, 1993; SILVA et al., 1994).
Enclosed in this general interest to
search for less harmful, but highly active
chemoterapic drugs, we analyzed the
genotoxicity of the following new synthesized
drugs: (1) 3-(3’-nitrophenyl)-1,2,4 triazole-
[4,3-b]-benzothiazol (VN-3) and (2) 3-(4’-
c y a n o p h e n y l ) - 1 , 2 , 4 - t r i a z o l e [ 4 , 3 -
b]benzothiazol (ECB-93), both derived from
benzothiazol (triazole); and (3) 4-(3’, 4’-
methylenedioxybenzilidene)-pyridine
carboxilic acid hydrazide (ECM-1) and (4)
4-(4’-nitrobenzilidene)-pyridine carboxilic
acid hydrazide (ECM-4), both from isoniazid
(hydrazide).
The mutagenic effect of these derivatives
was analyzed by the micronucleus (MN)  assay
in mice, and by the Salmonella/microsome
assay. The first detects clastogenic and





1,2,4 triazole-[4,3-b]-benzothiazol and 3-
(4’-cyanophenyl)-1,2,4-triazole[4,3-
b]benzothiazol that were synthesized from
2-aminobenzothiazol, while  4-(3’, 4’-
methylenedioxybenzilidene)-pyridine
carboxilic acid hydrazide and 4-(4’-
nitrobenzilidene)-pyridine carboxilic acid
hydrazide from isoniazide (Fig. 1).  These
compounds were synthesized by the
Laboratory of Organic Drug Synthesis,
Pharmacy Faculty of the Federal University
of the State of Rio Grande do Sul.
Micronucleus Assay
Animals
Two mice strains were chosen: CF-1,
for s-triazoles, and Swiss Webster, for
hydrazides.  CF-1 mice were supplied by
the animal house of the Federal University
of Rio Grande do Sul - UFRGS, and Swiss
Webster by the Department of Agriculture.
The animals were housed in propylene
cages with wood shaving on the floor and
caged by gender. Bottled tap water and rats
diet (Nuvital, PR) were provided ad libitum.
The room was maintained at stable
temperature (23 to 25 0C). The mice were
used in the test after, at least, a week of
acclimation. The animals used weighted
about 20 g, and were 5-7 weeks old.  In the
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Micronucleus Test, ten mice (five for each
gender) per group of analysis were dosed.
In vivo mouse erythrocyte micronucleus
assay
Each complete test was made according
a report of the U.S. Environmental Protection
Agency Gene-Tox program (MAVOURNIN
et al., 1990).  At first, preliminary tests were
performed to evaluate the toxicity of the
products. To determine the maximum
tolerated dose (MTD), four mice were dosed
with a single dose of 500, 1000 and 2000 mg/
kg body weight,  observed during a period
of 72 h, for each drug. The MTD was defined
by LD50 (letal dose) and observation of toxic
effects. They were treated by oral gavage with
a volume of  0,1 ml/10g of body weigh of
mouse.  In the test, the animals were dosed
with determined MTD, and were killed 24
and 48 h after treatment.  Besides the two
test groups, negative (orally dosed with
vehicle: for triazoles corn oil and for
hidrazydes water) and positive (orally dosed
with 60 mg/kg of cyclophosphamide
(EDUXAN) diluted in water) controls were
used.  The bone marrow  was extracted from
the two femurs. Smear was made from ma-
terial directly homogenized  on two slides,
with a drop of fetal calf serum.  The slides
were stained with 5% Giemsa, and coded for
a  “blind” analyzis.   To avoid false negatives,
the polychromatic erythrocyte (PCE):
normochromatic erythrocyte (NCE) ratio in
1000 erythrocytes was determined, as a
measure of toxicity of the product on the
bone marrow.  The frequency of
micronucleated cells  was analyzed in 2000
PCE/mouse.  The two test groups were
compared to the negative controls by gender,
separately and combined. Statistical analysis




The Salmonella typhimurium strains
TA98 and TA100, as described by MARON
& AMES (1983), were kindly provided by
Dr. B.N. Ames, University of California,
Berkeley, CA (U.S.A.).
Microsonal fraction
The microsonal  fraction S9 was prepared
from livers of Spregue-Dauley rats pretreated
with polychlorinated biphenyl mixture
(Aroclor 1254), purchased from Molecular
Toxicology Inc. (MoltoxTM). The S9-mix
metabolic activation mixture  was prepared
according to MARON & AMES  (1983).
Salmonella/ microsome assay
Mutagenicity was assayed by the
preincubation procedure  (MARON &
AMES, 1983), with Salmonella typhimurium
strains TA98 and TA100 using various
concentrations of triazoles and hydrazides
derivatives with or without S9-mix. The
mixture consisting of test compound,
500ml of S9-mix (in tests with metabolic
activation) and 100ml of the bacterial
suspension (1-2 x 109cells/ml), was
preincubated for 20 min at 37ºC without
shaking. Then, 2000ml of top agar (0.55%
agar, 0.55% NaCl, 50mM L-histidine,
50mM biotin, pH 7.4, 45ºC) was added in
the test tube and poured onto a Petri dish
with minimal agar (1.5% agar, Vogel-Bonner
E medium, containing 2% glucose). All
assays were carried out in triplicate. After
incubation for 48h, colonies (His+ revelants)
were counted and the results were expressed
as mutagenic index (Ml).
For determination of the cytotoxic
effects after preincubation the mixture as
indicated above was diluted in phosphate
buffer (0.02M, pH 7.4) to obtain a
suspension containing 1-2 x 103cells/ml.
Suitable aliquots of this suspension were
plated on nutrient agar (0.8% bacto nutrient
broth (Difco), 0.5% NaCl and 1.5% agar) in
triplicate. Plates were incubated at 37ºC for
48h before counting the surviving colonies.
Negative (appropriate solvent - water
for hydrazides and corn oil for triazoles)
and positive (5mg sodium azide in water
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per plate for TA100 strain; 0.5mg 4-
nitroquinoline 1-oxide (4-NQO) in DMSO
per plate for TA98) controls were included
in each assay. Aflatoxin B1 (1mg per plate)
was used as positive control for the tests
with metabolic activation for both strains.
The results were classified positive
according to VARGAS et al. (1995), i.e., the
number of revertants double the
spontaneous frequency accompanied by a
reproducible dose-response curve.
Significance was evaluated by the
SALMONEL software (MYERS et al.,
1991). When one of  these criteria was not
met, the samples were considered to show
signs of a negative response. The sample
was classified as cytotoxic when cell




Based on the toxicity test (Table 1) and
recommendations of U.S. Environmental
Protection Agency Gene-Tox program, the
MTD determined were:  (a)  VN-3: 2000
mg/kg;  (b) ECB-93: 2000mg/kg;  (c)
ECM-1: 500 mg/kg and (d) ECM-4: 2000
mg/kg.  The results for bone marrow
toxicity can be seen in the right column of
tables 2-5.  Mortalities in the test occurred
only for 2 groups: ECB-93 and ECM-4.
To the compounds VN-3 (48h), ECB-93
(24 and 48h), ECM-1 (24h) and ECM-4
(24 and 48 h) reductions in the PCE:NCE
ration were observed.  The lowest ratio was
0.4 (ECB-93 - 24h).  Evaluation of the
induction of MN revealed results that  were
not statistically different from the negative
control for all four substances.
Salmonella Mutagenicity
Assay
Tables 6 and 7  show the mutagenic
index (Ml) in S.typhimurium TA98 and
Ta100 obtained after triazoles and
hydrazides derivatives treatment with and
without metabolic activation.
In contrast for the positive control,
the products VN-3, ECB-93, ECM-1 and
ECM-4, were not mutagenic in S.
typhimurium TA98 and TA100 strains
neither in presence nor in absence of
metabolic activation by S9-mix.
Discussion
The drugs VN-3, ECB-93, ECM-1 and
ECM-4 neither induce chromosome damage
in the mouse bone marrow micronucleus
assay nor gene mutations in the Salmonella/
microsome assay.  The compounds VN-3 (48
h), ECB-93 (24 and 48 h), ECM-1 (24 h)
and ECM-4 (24 and 48 h) caused toxicity in
vivo at the dose level used (500-2000 mg/kg).
The PCE reductions observed indicate that
VN-3 (48h), ECB-93 (24h and 48h), ECM-
1 (24h) and ECM-4 (24h and 48h) cause
inhibition in the division and maturation of
erythroblasts. This can be explained by the
principal mechanism of action of
chemotherapeutic drugs, i.e.,  inhibition of
DNA synthesis (SIMS & GUTTERIDGE,
1978; HOWELLS, 1985; CRAIG &
STITZEL, 1986; KOROLKOVAS, 1988).
Although some of these compounds
show “alert structure”, structure-activity
relationships in mutagenicity and
carcinogenicity (TENNANT & ASHBY,
1991), the result can be explained by
mechanism that protect against oxidative
degradation of DNA, like antioxidant
enzymes and aminoacids (BALAGUER,
1990; CLAYSON et al., 1994).
ECB-93, s-triazole, does not have any
structure that can  induce  damage and
did not induce micronuclei, or gene
mutation.  So,  this result confirms that
compounds without  “alert structure”
hardly are mutagens (ASHBY &
TENNANT, 1991).  The hydrazides ECM-
1 and ECM-4, due to the fact that they are
isoniazide derivatives and produce
hydrazine (-NH-N=CH-), which is keep in
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circulation after treatment (BRAUN et al.,
1984), these compounds may produce
mutagenic effects.  ECM-4 also contains
the nitro aromatic group, which is an anion
radical that can cause damage to the cell.
Despite these chemical characteristics,
ECM-1 and ECM-4 showed negative
results in the micronucleus assay. The
ECM-4 molecule has a part that is
negatively charged, due to nitro group, but
there is also a positively charged group due
to pyridine group.  Therefore it is possible
to explain the negative result by the
existence of charge transfer complexes or
other kind of associations.  A similar
situation has been described for panidazole
(VOOGD et al., 1992). The other s-triazole,
VN-3, contain a nitro aromatic (-NO2)
group, that in most cases indicates
mutagenic (70%) and/or carcinogenic
(86%) activity (SHELBY, 1988;
TENNANT & ASHBY, 1991).  However
are these relations, VN-3 did not
demonstrate mutagenic activity, like others
drugs: e.g.  metronidazole (HEDDLE et
al., 1983), pentachloronitrobenzene and 1-
nitronaphtalene (ASHBY & TENNANT,
1988).  This “alert structure”, present in
these compounds, can be inactivated
biologically by an excretion of this kind of
structure and by a fast detoxification in vivo
(ASHBY & TENNANT, 1988).
As our results did not indicate
genotoxic effects of the test compounds,
they enabled the further investigation and
evaluation of the pharmacological potential
of these products.
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Figure 1. Nomenclature and chemical structural formula of benzothiazols and  isoniazids new derivatives



























Table 1. Mortality frequency (%) observed to different doses for VN-3, ECB-93, ECM-1 and ECM-4 on four mice
tested. * Toxicity signs
Mortality with Treatment (mg/kg)
Substance Exposition (h) 500 (mg/kg) 1000 (mg/kg) 2000 (mg/kg)
VN-3 24 zero zero zero
48 zero zero zero
72 zero zero zero
ECB-93 24 zero zero zero
48 zero zero zero
72 Zero zero zero
ECM-1 24 Zero* 50 50
48 Zero 50 50
72 Zero zero zero
ECM-4 24 zero zero zero
48 zero zero zero
72 zero zero zero
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Table 2. Number of micronucleated polychromatic erytrocytes (mPCE) of bone marrow of mice treated  with  VN-3 (2000
mg/kg) and  frequency of polychromatic erytrocytes (PCE-%)
Table 3. Number of micronucleated polychromatic erytrocytes (mPCE) of bone marrow of mice treated with ECB-93
(2000 mg/kg) and frequency of polychromatic erytrocytes (PCE-%).
       mPCE PCE (%)
Group Gender Individual
(mPCE/2000 PCE)
          Per Gender
   Σx          M ± S.D.
Per Group
M  ± S.D.
     mPCE (‰)
Positive    M    94  61  92  119   91  457** 91.4 ± 21.0   84.5 ± 20.0 42.3** 46
Control    F    84  96  82    81   45  388** 77.6 ± 19.0
Negative    M      4    7    6    10    8    35   7.0 ± 2.2     6.9 ± 2.4 3.5 36
Control    F      9  10    7     4     4    34   6.8 ± 2.8
Treated    M      7    4  12     7     6    36   7.2 ± 3.0     7.4 ± 2.6 3.7 24
24h    F      5  10    8    (?)  (D)    23(a)   7.7 ± 2.5
Treated    M      7    3    7     5     3    25   5.0 ± 2.0     5.3 ± 2.1 2.7 33
48h    F      3    9    6     6     4    28   5.6 ± 2.3
** P<0.001; M ± S.D.= mean ± standard deviation; (?)= insuficient number of PCE; (D)= died; (a)= Σ3 animals;
(b) =Σ8 animals
Table 4. Number of micronucleated polychromatic erytrocytes (mPCE) of bone marrow of mice treated with ECM-1
(500 mg/kg) and frequency of polychromatic erytrocytes (PCE-%).
       mPCE PCE (%)
Group Gender Individual
(mPCE/2000 PCE)
          Per Gender
   Σx           M ± S.D.
Per Group
 M  ± S.D.
     mPCE (‰)
Positive    M     25  26  16  32  12  118**  23.6 ± 6.3   28.3 ± 8.0 14.2** 67
Control    F     43  23  33  33  33  165**  33.0 ± 7.1
Negative    M      2    3    1    2    5 13    2.6 ± 1.5     2.1 ± 1.5 1.2 56
Control    F      3    1    1    0    3 8    1.6 ± 1.3
Treated    M      0    2    1    2    2 7    1.4 ± 0.9     1.5 ± 0.7 0.8 48
24h    F      1    2    2    2    1 8    1.6 ± 0.5
Treated    M      1    0    2    1    1 5    1.0 ± 0.7     1.2 ± 0.9 0.6 73
48h    F      0    1    3    1    2 7    1.4 ± 1.1
** P<0.001; M ± S.D.= mean ± standard deviation
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Table 5. Number of micronucleated polychromatic erytrocytes (mPCE) of bone marrow of mice treated with ECM-4
(2000 mg/kg) and frequency of polychromatic erytrocytes (PCE-%).
Table 6. Response to hydrazides (ECM-1 and ECM-4) and s-triazoles (VN-3 and ECB-93) derivatives in the
Salmonella/microsome assay, strains TA98 and TA100, without metabolic activation.
                         TA98 TA100
Agent Dose(μg) RN M ± S.D. MI Dose(μg) RN M ± S.D. MI





































































































































C+= positive control group; RN= revertant number; M ± S.D.= mean ±  standard deviation; MI= mutagenic index
Table 7. Response to hydrazides (ECM-1 and ECM-4) and s-triazoles (VN-3 and ECB-93) derivatives in the
Salmonella/microsome assay, strains TA98 and TA100, with metabolic activation
                         TA98 TA100
Agent Dose(μg) RN M ± S.D. MI Dose(μg) RN M ± S.D. MI




































































































































C+= positive control group; RN= revertant number; M ± S.D.= mean ±  standard deviation; MI= mutagenic index
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